(IVVD) Invivyd - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US46187W1071

Antibody, Covid-19, Influenza, Prevention, Treatment

Biotechnology
Market Cap in USD: 585m
IPO / Inception: 2021-08-06
12m vs SPY: 435%

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 131%
Value at Risk 5%th 163%
Relative Tail Risk -24.42%
Reward TTM
Sharpe Ratio 1.52
Alpha 532.82
CAGR/Max DD 0.12
Character TTM
Hurst Exponent 0.420
Beta 0.897
Beta Downside 1.407
Drawdowns 3y
Max DD 92.90%
Mean DD 57.52%
Median DD 57.34%

Description: IVVD Invivyd December 22, 2025

Invivyd, Inc. (NASDAQ:IVVD) is a U.S.-based biopharma focused on antibody-based therapeutics for infectious diseases, primarily COVID-19. Its lead assets are PEMGARDA (pemivibart), a half-life-extended monoclonal antibody in late-stage trials for prophylaxis, and Adintrevimab, currently in Phase 2/3 for both prevention and treatment. The pipeline also includes preclinical candidate VYD2311 and discovery-stage programs targeting seasonal influenza and additional COVID-19 antibodies, developed under a discovery partnership with Adimab, LLC.

Key operational metrics (as of the most recent 10-Q) show cash and cash equivalents of roughly $45 million, providing runway into 2025 assuming current burn rates. The infectious-disease antibody market is projected to grow at a CAGR of ~12% through 2030, driven by continued demand for rapid-deployment biologics and government procurement programs. Recent sector trends-such as the FDA’s accelerated pathways for monoclonal antibodies and heightened payer focus on outpatient-administered therapies-are favorable to Invivyd’s commercial strategy.

For a deeper quantitative assessment, you might explore ValueRay’s detailed analyst models for IVVD.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-59.9m TTM) > 0 and > 6% of Revenue (6% = 3.00m TTM)
FCFTA -0.58 (>2.0%) and ΔFCFTA 60.94pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 130.4% (prev 497.4%; Δ -366.9pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.58 (>3.0%) and CFO -80.3m <= Net Income -59.9m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 2.47 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (170.2m) change vs 12m ago 42.41% (target <= -2.0% for YES)
Gross Margin 93.34% (prev 86.74%; Δ 6.60pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 33.24% (prev 9.01%; Δ 24.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -33.91 (EBITDA TTM -58.5m / Interest Expense TTM -1.82m) >= 6 (WARN >= 3)

Altman Z'' -43.27

(A) 0.47 = (Total Current Assets 109.8m - Total Current Liabilities 44.5m) / Total Assets 139.2m
(B) -6.78 = Retained Earnings (Balance) -943.4m / Total Assets 139.2m
warn (B) unusual magnitude: -6.78 — check mapping/units
(C) -0.41 = EBIT TTM -61.7m / Avg Total Assets 150.5m
(D) -20.47 = Book Value of Equity -943.4m / Total Liabilities 46.1m
Total Rating: -43.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 40.35

1. Piotroski 1.50pt
2. FCF Yield -16.00%
3. FCF Margin data missing
4. Debt/Equity 0.03
5. Debt/Ebitda 1.41
6. ROIC - WACC (= -84.86)%
7. RoE -92.97%
8. Rev. Trend 87.36%
9. EPS Trend 73.42%

What is the price of IVVD shares?

As of January 15, 2026, the stock is trading at USD 2.60 with a total of 4,543,434 shares traded.
Over the past week, the price has changed by +8.33%, over one month by +17.12%, over three months by +59.51% and over the past year by +542.45%.

Is IVVD a buy, sell or hold?

Invivyd has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy IVVD.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the IVVD price?

Issuer Target Up/Down from current
Wallstreet Target Price 10 284.6%
Analysts Target Price 10 284.6%
ValueRay Target Price 2.9 12.7%

IVVD Fundamental Data Overview January 10, 2026

P/E Forward = 27.8552
P/S = 11.6936
P/B = 7.6051
Revenue TTM = 50.0m USD
EBIT TTM = -61.7m USD
EBITDA TTM = -58.5m USD
Long Term Debt = 2.68m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.08m USD (from shortTermDebt, last quarter)
Debt = 2.68m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -82.3m USD (from netDebt column, last quarter)
Enterprise Value = 502.8m USD (585.1m + Debt 2.68m - CCE 85.0m)
Interest Coverage Ratio = -33.91 (Ebit TTM -61.7m / Interest Expense TTM -1.82m)
EV/FCF = -6.25x (Enterprise Value 502.8m / FCF TTM -80.4m)
FCF Yield = -16.00% (FCF TTM -80.4m / Enterprise Value 502.8m)
FCF Margin = -160.8% (FCF TTM -80.4m / Revenue TTM 50.0m)
Net Margin = -119.6% (Net Income TTM -59.9m / Revenue TTM 50.0m)
Gross Margin = 93.34% ((Revenue TTM 50.0m - Cost of Revenue TTM 3.33m) / Revenue TTM)
Gross Margin QoQ = 91.71% (prev 94.19%)
Tobins Q-Ratio = 3.61 (Enterprise Value 502.8m / Total Assets 139.2m)
Interest Expense / Debt = 140.1% (Interest Expense 3.75m / Debt 2.68m)
Taxrate = 21.0% (US default 21%)
NOPAT = -48.7m (EBIT -61.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.47 (Total Current Assets 109.8m / Total Current Liabilities 44.5m)
Debt / Equity = 0.03 (Debt 2.68m / totalStockholderEquity, last quarter 93.1m)
Debt / EBITDA = 1.41 (negative EBITDA) (Net Debt -82.3m / EBITDA -58.5m)
Debt / FCF = 1.02 (negative FCF - burning cash) (Net Debt -82.3m / FCF TTM -80.4m)
Total Stockholder Equity = 64.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.76% (Net Income -59.9m / Total Assets 139.2m)
RoE = -92.97% (Net Income TTM -59.9m / Total Stockholder Equity 64.4m)
RoCE = -91.97% (EBIT -61.7m / Capital Employed (Equity 64.4m + L.T.Debt 2.68m))
RoIC = -75.68% (negative operating profit) (NOPAT -48.7m / Invested Capital 64.4m)
WACC = 9.18% (E(585.1m)/V(587.8m) * Re(9.22%) + (debt cost/tax rate unavailable))
Discount Rate = 9.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 24.46%
Fair Price DCF = unknown (Cash Flow -80.4m)
EPS Correlation: 73.42 | EPS CAGR: 49.94% | SUE: 0.08 | # QB: 0
Revenue Correlation: 87.36 | Revenue CAGR: 87.20% | SUE: 0.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.20 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.14 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+68.2% | Growth Revenue=+146.6%

Additional Sources for IVVD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle